Enveda secures $311M to bring more nature-derived AI drugs into clinical trials

Enveda, an AI‑driven biotech that designs nature‑derived drug candidates, has raised $311 million in a financing round that values the company at $2 billion. The firm is currently testing treatments for skin disorders and for preserving weight loss after discontinuing GLP‑1 therapies.

Summary written by Kernelia from the original article by TechCrunch AI. The story and its rights belong to its author.